The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study
Abstract Purpose Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab,...
Saved in:
Published in | American journal of health-system pharmacy Vol. 79; no. 24; pp. 2222 - 2229 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
05.12.2022
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Purpose
Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis.
Methods
A retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19–specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis.
Results
A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis. |
---|---|
AbstractList | Abstract
Purpose
Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis.
Methods
A retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19–specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis.
Results
A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis. PURPOSEDespite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis. METHODSA retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19-specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis. RESULTSA total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis. |
Author | Polsky, Bruce Jones, Simon Bosworth, Brian P Lighter, Jennifer L Iturrate, Eduardo Viswanathan, Anand François, Fritz R. Nagler, Arielle Petrilli, Christopher M Kalkut, Gary Horwitz, Leora I Phillips, Michael Volpicelli, Frank M Dapkins, Isaac |
Author_xml | – sequence: 1 givenname: Arielle surname: R. Nagler fullname: R. Nagler, Arielle – sequence: 2 givenname: Leora I surname: Horwitz fullname: Horwitz, Leora I – sequence: 3 givenname: Simon surname: Jones fullname: Jones, Simon – sequence: 4 givenname: Christopher M surname: Petrilli fullname: Petrilli, Christopher M – sequence: 5 givenname: Eduardo surname: Iturrate fullname: Iturrate, Eduardo – sequence: 6 givenname: Jennifer L surname: Lighter fullname: Lighter, Jennifer L – sequence: 7 givenname: Michael surname: Phillips fullname: Phillips, Michael – sequence: 8 givenname: Brian P surname: Bosworth fullname: Bosworth, Brian P – sequence: 9 givenname: Bruce surname: Polsky fullname: Polsky, Bruce – sequence: 10 givenname: Frank M surname: Volpicelli fullname: Volpicelli, Frank M – sequence: 11 givenname: Isaac surname: Dapkins fullname: Dapkins, Isaac – sequence: 12 givenname: Anand surname: Viswanathan fullname: Viswanathan, Anand – sequence: 13 givenname: Fritz surname: François fullname: François, Fritz – sequence: 14 givenname: Gary surname: Kalkut fullname: Kalkut, Gary |
BookMark | eNotkMtqwzAUREVJoUnaXT9Ayy7q5lryS92F9BUIZJN2K2T5mijYkmvJpenX1yFZzTAMw3BmZGKdRULuY3iKQfCFOuy7xd-v0kykV2QapzyNmACYjB5yETEo2A2ZeX8AiFkB2ZTI3R6paTulA3U1XW2_1i9RLGjrrNONs6qhygZTusqgp85S3Rhr9Bi7IWjXon-mS9pj6J3vUAfzg1S7vesD9WGojrfkulaNx7uLzsnn2-tu9RFttu_r1XITaQ5ZiHKox2-lwKLETJVJpbMiVQzy0VR5BilTseBZxhCUAMxyUSgsEpFAoaHgjM_Jw3m36933gD7I1niNTaMsusFLlrN0XEgYH6uP56oeP_sea9n1plX9UcYgTxzliaO8cOT_AAFpKQ |
CitedBy_id | crossref_primary_10_7326_M22_1286 crossref_primary_10_1177_10600280231222465 |
Cites_doi | 10.1056/NEJMoa2108163 10.1038/nature02145 10.1016/j.ajem.2021.07.050 10.1056/NEJMoa2107934 10.1093/infdis/jiab377 10.1126/science.abe2402 10.7326/M16-2607 10.1056/NEJMoa2109682 10.18637/jss.v042.i07 10.1038/s41586-020-2349-y 10.1080/19420862.2021.1919285 10.1093/cid/ciab912 10.1002/sim.6880 10.1056/NEJMoa2035002 10.1001/jama.2021.0202 10.1038/s41586-020-2772-0 10.1056/NEJMoa2029849 10.1186/s40001-021-00524-8 10.1016/j.eclinm.2021.101102 10.1056/NEJMoa2102685 10.1172/JCI151697 |
ContentType | Journal Article |
DBID | AAYXX CITATION 7X8 |
DOI | 10.1093/ajhp/zxac295 |
DatabaseName | CrossRef MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1535-2900 |
EndPage | 2229 |
ExternalDocumentID | 10_1093_ajhp_zxac295 |
GroupedDBID | --- .XZ 04C 0R~ 23M 36B 4.4 48X 5GY 5RE 5RS 5WD 6J9 6PF AABZA AACZT AAIMJ AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL AAYEP AAYXX ABCQX ABDBF ABJNI ABMNT ABNHQ ABPQP ABPTD ABQNK ABWST ABXVV ACFRR ACGFO ACIWK ACPRK ACUTJ ACYHN ADBBV ADGKP ADGZP ADIPN ADOJX ADQBN ADRTK ADVEK AEGXH AELWJ AENEX AETBJ AFFZL AFGWE AFRAH AFXAL AGINJ AGQXC AGUTN AIAGR AJEEA ALMA_UNASSIGNED_HOLDINGS ATGXG BCRHZ BEYMZ BMSDO C45 CITATION CS3 EAD EAP EAS EBC EBD EBS ECF ECT ECV EHN EIHBH EJD EMB EMK EMOBN ENC ENERS EPL EPT EST ESX EX3 F5P FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT H13 IAO IHR INH INR J5H KOP KSI KSN L7B M5~ MHKGH MK0 MV1 NLBLG NOMLY NOYVH O9- OAUYM OB4 OBOKY OCZFY ODMLO OFXIZ OJZSN OPAEJ OVD OVIDX OWPYF P2P PONUX Q~Q R0Z RHI ROX RUSNO SJN SV3 TEORI TMA TSH TUS VVN WH7 WOW WQ9 YFH YOC YXANX 7X8 |
ID | FETCH-LOGICAL-c306t-70f082b9e8be6ab4dc685a207dc6d76052a193662e0a90e6798ae849408c08323 |
ISSN | 1079-2082 |
IngestDate | Fri Oct 25 05:45:53 EDT 2024 Mon Oct 14 04:03:30 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 24 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c306t-70f082b9e8be6ab4dc685a207dc6d76052a193662e0a90e6798ae849408c08323 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://academic.oup.com/ajhp/article-pdf/79/24/2222/47562243/zxac295.pdf |
PQID | 2725193423 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_2725193423 crossref_primary_10_1093_ajhp_zxac295 |
PublicationCentury | 2000 |
PublicationDate | 2022-12-05 |
PublicationDateYYYYMMDD | 2022-12-05 |
PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-05 day: 05 |
PublicationDecade | 2020 |
PublicationTitle | American journal of health-system pharmacy |
PublicationYear | 2022 |
References | Weinreich (2022120508530948400_CIT0009) 2021; 384 Benton (2022120508530948400_CIT0002) 2020; 588 VanderWeele (2022120508530948400_CIT0023) 2017; 167 Dougan (2022120508530948400_CIT0005) 2021; 385 Liu (2022120508530948400_CIT0026) 2021; 13 Weinreich (2022120508530948400_CIT0015) 2021; 385 Arpino (2022120508530948400_CIT0017) 2016; 35 Li (2022120508530948400_CIT0003) 2003; 426 Sekhon (2022120508530948400_CIT0021) 2011; 42 Gupta (2022120508530948400_CIT0011) 2021; 385 Ganesh (2022120508530948400_CIT0013) 2021; 131 Cannas (2022120508530948400_CIT0020) 2019 Gottlieb (2022120508530948400_CIT0007) 2021; 325 SeyedAlinaghi (2022120508530948400_CIT0016) 2021; 26 Chen (2022120508530948400_CIT0008) 2021; 384 Razonable (2022120508530948400_CIT0014) 2021; 40 O’Brien (2022120508530948400_CIT0006) 2021; 385 Centers for Disease Control and Prevention (2022120508530948400_CIT0027) Baum (2022120508530948400_CIT0001) 2020; 370 Pinto (2022120508530948400_CIT0004) 2020; 583 R Core Team (2022120508530948400_CIT0019) 2019 Dougan (2022120508530948400_CIT0010) 2021; 75 Pearl (2022120508530948400_CIT0022) 2000 Ganesh (2022120508530948400_CIT0024) 2021; 224 Ash (2022120508530948400_CIT0025) 2021; 50 Kreuzberger (2022120508530948400_CIT0012) 2021; 9 Chen (2022120508530948400_CIT0018) 2018 |
References_xml | – volume: 385 start-page: e81 issue: 23 year: 2021 ident: 2022120508530948400_CIT0015 article-title: REGEN-COV antibody combination and outcomes in outpatients with Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2108163 contributor: fullname: Weinreich – volume: 426 start-page: 450 issue: 6965 year: 2003 ident: 2022120508530948400_CIT0003 article-title: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus publication-title: Nature doi: 10.1038/nature02145 contributor: fullname: Li – year: 2018 ident: 2022120508530948400_CIT0018 contributor: fullname: Chen – volume: 50 start-page: 129 year: 2021 ident: 2022120508530948400_CIT0025 article-title: Real world utilization of REGEN-COV2 at a community hospital publication-title: Am J Emerg Med doi: 10.1016/j.ajem.2021.07.050 contributor: fullname: Ash – volume: 385 start-page: 1941 issue: 21 year: 2021 ident: 2022120508530948400_CIT0011 article-title: Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab publication-title: N Engl J Med doi: 10.1056/NEJMoa2107934 contributor: fullname: Gupta – volume: 224 start-page: 1278 issue: 8 year: 2021 ident: 2022120508530948400_CIT0024 article-title: Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019 publication-title: J Infect Dis doi: 10.1093/infdis/jiab377 contributor: fullname: Ganesh – volume: 370 start-page: 1110 issue: 6520 year: 2020 ident: 2022120508530948400_CIT0001 article-title: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters publication-title: Science doi: 10.1126/science.abe2402 contributor: fullname: Baum – year: 2019 ident: 2022120508530948400_CIT0020 contributor: fullname: Cannas – volume: 167 start-page: 268 issue: 4 year: 2017 ident: 2022120508530948400_CIT0023 article-title: Sensitivity analysis in observational research: introducing the E-value publication-title: Ann Intern Med doi: 10.7326/M16-2607 contributor: fullname: VanderWeele – volume: 385 start-page: 1184 issue: 13 year: 2021 ident: 2022120508530948400_CIT0006 article-title: Subcutaneous REGEN-COV antibody combination to prevent Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2109682 contributor: fullname: O’Brien – volume: 42 start-page: 1 issue: 7 year: 2011 ident: 2022120508530948400_CIT0021 article-title: Multivariate and propensity score matching software with automated balance optimization: the matching package for R publication-title: J Stat Softw doi: 10.18637/jss.v042.i07 contributor: fullname: Sekhon – volume: 583 start-page: 290 issue: 7815 year: 2020 ident: 2022120508530948400_CIT0004 article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody publication-title: Nature doi: 10.1038/s41586-020-2349-y contributor: fullname: Pinto – volume-title: Causality: Models, Reasoning, and Inference year: 2000 ident: 2022120508530948400_CIT0022 contributor: fullname: Pearl – volume: 13 start-page: 1919285 issue: 1 year: 2021 ident: 2022120508530948400_CIT0026 article-title: 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro publication-title: MAbs doi: 10.1080/19420862.2021.1919285 contributor: fullname: Liu – volume: 75 start-page: e440 issue: 1 year: 2021 ident: 2022120508530948400_CIT0010 article-title: A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load publication-title: Clin Infect Dis doi: 10.1093/cid/ciab912 contributor: fullname: Dougan – volume: 35 start-page: 2074 issue: 12 year: 2016 ident: 2022120508530948400_CIT0017 article-title: Propensity score matching with clustered data. An application to the estimation of the impact of caesarean section on the Apgar score publication-title: Stat Med doi: 10.1002/sim.6880 contributor: fullname: Arpino – volume: 384 start-page: 238 issue: 3 year: 2021 ident: 2022120508530948400_CIT0009 article-title: REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2035002 contributor: fullname: Weinreich – volume: 325 start-page: 632 issue: 7 year: 2021 ident: 2022120508530948400_CIT0007 article-title: Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2021.0202 contributor: fullname: Gottlieb – volume: 588 start-page: 327 issue: 7837 year: 2020 ident: 2022120508530948400_CIT0002 article-title: Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion publication-title: Nature doi: 10.1038/s41586-020-2772-0 contributor: fullname: Benton – volume: 384 start-page: 229 issue: 3 year: 2021 ident: 2022120508530948400_CIT0008 article-title: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2029849 contributor: fullname: Chen – volume: 26 start-page: 51 issue: 1 year: 2021 ident: 2022120508530948400_CIT0016 article-title: Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review publication-title: Eur J Med Res doi: 10.1186/s40001-021-00524-8 contributor: fullname: SeyedAlinaghi – volume: 9 start-page: CD013825 year: 2021 ident: 2022120508530948400_CIT0012 article-title: SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19 publication-title: Cochrane Database Syst Rev contributor: fullname: Kreuzberger – volume: 40 start-page: 101102 year: 2021 ident: 2022120508530948400_CIT0014 article-title: Casirivimab-imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19 publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2021.101102 contributor: fullname: Razonable – volume-title: R: A Language and Environment for Statistical Computing year: 2019 ident: 2022120508530948400_CIT0019 contributor: fullname: R Core Team – volume: 385 start-page: 1382 issue: 15 year: 2021 ident: 2022120508530948400_CIT0005 article-title: Bamlanivimab plus etesevimab in mild or moderate Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2102685 contributor: fullname: Dougan – volume: 131 start-page: e151697 issue: 19 year: 2021 ident: 2022120508530948400_CIT0013 article-title: Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19 publication-title: J Clin Invest doi: 10.1172/JCI151697 contributor: fullname: Ganesh – ident: 2022120508530948400_CIT0027 contributor: fullname: Centers for Disease Control and Prevention |
SSID | ssj0012806 |
Score | 2.4151912 |
Snippet | Abstract
Purpose
Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more... PURPOSEDespite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data... |
SourceID | proquest crossref |
SourceType | Aggregation Database |
StartPage | 2222 |
Title | The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study |
URI | https://search.proquest.com/docview/2725193423 |
Volume | 79 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbK9oKEJhggdkNGgr1k7hzXuZi3bGMaiMsEHdpb5CQODJWm6lKJ7UfxGzmOnThFfRi8pFFUO63Pp-PLOd93EHoJa4KMytInSlBOuK98IkZUkcgPVFgyVcomiebDx_Dsgr-7DC4Hg9-9rKVFnQ3z25W8kv-xKjwDu2qW7D9YtusUHsA92BeuYGG43tnGjuZ4_Onr2xPiCw_eX-WT5ogPxu0qq3SmoI4KdDTIalHD7zHpcIk3V_W8aimXni6ZO697urOtRm0b2-mJTRgWJTFy0N7MyGB3h_Sfh-C8v1mqYQJ78snEwUhLDze1ZL33CmDoTm-76gFfrn66HIGm8tfEcLl7ggj2MNceW7CmggoNep6WRgKMaSoPDVXrfQPCBKV992xqzVgYMt53toyx3sStK5OvnBSMYJb88X0GH7e_ZM5MXc9l9e2_ZsUuV9FE6Uepbp_a1vfQOgPHBh51PTk6OTrt4lY6Tm2yXM2fs1QLaH-o2x_a9suLoOU1QLOwGT9EG3ZHghMDr0dooKabaP_c2vIAjx1D7_oA7-NzJ3Z-s4kemHNfbOhsj1EKX8cGk7gqcYtJ7DCJHSZxNcUtJnGLydc4wUuIxAaRuEHkE3Rx-mZ8fEZsEQ-Sw260JhEtYRwyoeJMhTLjRR7GgWQ0gpsigs00k-AvwpApKgVVOigoVcwFp3EO2wM2eorWpgC8ZwhrqcSY8VKTyblgMi6KKBfQL_OLUjC6hV61o5rOjFZLusp6W-hFO-QpOFMdIZNTVS2uUxZpIrcWxdy-Y1876L5D9y5aq-cLtQfL1Dp7brHxB4_DmOI |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+impact+of+COVID-19+monoclonal+antibodies+on+clinical+outcomes%3A+A+retrospective+cohort+study&rft.jtitle=American+journal+of+health-system+pharmacy&rft.au=R.+Nagler%2C+Arielle&rft.au=Horwitz%2C+Leora+I&rft.au=Jones%2C+Simon&rft.au=Petrilli%2C+Christopher+M&rft.date=2022-12-05&rft.issn=1079-2082&rft.eissn=1535-2900&rft.volume=79&rft.issue=24&rft.spage=2222&rft.epage=2229&rft_id=info:doi/10.1093%2Fajhp%2Fzxac295&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ajhp_zxac295 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-2082&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-2082&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-2082&client=summon |